Phytochemicals at the PPAR-NF-κB Interface: A Structured Narrative Review of Receptor Pharmacology, Inflammatory Signaling, and Translational Barriers.
6 affiliations
- 1Gomal Center of Pharmaceutical Sciences Faculty of Pharmacy Gomal University Dera Ismail Khan Pakistan gu.edu.pk.
- 2Department of Pharmacy Forman Christian College (A Chartered University) Lahore Pakistan fccollege.edu.pk.
- 3Independent Researcher Hérouville-Saint-Clair France.
- 4Faculty of Pharmaceutical Sciences Abasyn University Peshawar Pakistan abasyn.edu.pk.
- 5Department of Biology The University of Haripur Haripur Pakistan uoh.edu.pk.
- 6Para-Clinic Department Faculty of Medicine Bayazid Rokhan University Kabul Afghanistan.
Abstract
Background
The peroxisome proliferator-activated receptors (PPARs) and nuclear factor-κB (NF-κB) signaling axis serves as master molecular interface governing metabolic homeostasis and inflammatory resolution. Dysregulated reciprocal repression between PPAR-α/γ and NF-κB contributes to chronic inflammatory diseases, metabolic syndrome, and malignancy. Synthetic full agonists (e.g., thiazolidinediones and fibrates) are associated with clinical liabilities including adipogenesis, fluid retention, hepatotoxicity, and cardiovascular adverse effects, underscoring the need for safer modulators.Objective and rationale
This structured narrative review provides a rigorous mechanistic synthesis of plant derived phytochemicals with selective PPAR modulator (SPPARM) like pharmacology. We elucidate how distinct chemical classes may achieve targeted NF-κB transrepression with reduced transcriptional liability, summarize available ligand receptor binding data, and critically evaluate translational hurdles.Methods
A structured narrative review was conducted using a systematic style literature search across PubMed/MEDLINE, Scopus, and Web of Science from January 2000 through March 2026. In line with PRISMA 2020 principles for transparent reporting, original research articles were prioritized according to evidence type (clinical, preclinical, in vivo, and in vitro/in silico), with emphasis on pharmacodynamic metrics, binding kinetics (Ki, EC₅₀, and IC₅₀), receptor dependency validation (knockout, antagonism), and pharmacokinetic data.Results
Chemically diverse phytochemicals including flavonoids, neolignans, stilbenoids and terpenoids exhibit partial or subtype selective PPAR agonism in reporter and binding assays. Mechanistically, many favor anti-inflammatory transrepression over full coactivator-dependent transactivation, with evidence for corepressor recruitment and inhibition of NF-κB nuclear translocation in selected models. However, integrated analysis reveals a persistent disconnect between submicromolar in vitro potency and negligible systemic exposure of free parent compound (low Cmax, extensive glucuronidation/sulfation), compounded by frequent reliance on unvalidated docking simulations and PPAR-independent NF-κB inhibition.Conclusion
Phytochemicals with SPPARM-like pharmacology represent a promising but unvalidated paradigm for nonsteroidal inflammation control. Realizing their potential will require next-generation delivery systems (e.g., liposomes, nanoemulsions, and cyclodextrin complexes), mandatory genetic or pharmacological receptor validation, and biomarker-driven clinical trials that document target engagement at achievable human exposure levels.
Related
- Special Issue “Molecular Mechanism Discovery of the Bioactive Phytochemicals against Different Diseases Based on Network Pharmacology and Molecular Docking, 2nd Edition”
- MitoQ in sepsis-associated acute lung injury: redox pharmacology, mechanistic evidence, and translational perspectives
- Mapping the technology–demand interface: how brain organoid evolution is reshaping the translational landscape of stroke
- Extracellular vesicles at the periodontal immune–regenerative interface: coupled mechanisms and translational challenges
- STRATUM—structured framework for reporting, assessment, and translational utility of metagenomics
BibTeX
@article{rehman2026phytochemicals,
title = {{Phytochemicals at the PPAR-NF-κB Interface: A Structured Narrative Review of Receptor Pharmacology, Inflammatory Signaling, and Translational Barriers.}},
author = {Sabi Ur Rehman and Fazal Ur Rehman and Shafi Ullah Khan and Amir Zeb and Saleha Ashfaq and Shakir Ullah Khan and Waheed Ullah Hafiz},
journal = {PPAR research},
year = {2026},
month = oct,
doi = {10.1155/ppar/9577380},
url = {https://europepmc.org/article/MED/42960166},
note = {CC BY},
}
RIS
TY - JOUR
TI - Phytochemicals at the PPAR-NF-κB Interface: A Structured Narrative Review of Receptor Pharmacology, Inflammatory Signaling, and Translational Barriers.
AU - Sabi Ur Rehman
AU - Fazal Ur Rehman
AU - Shafi Ullah Khan
AU - Amir Zeb
AU - Saleha Ashfaq
AU - Shakir Ullah Khan
AU - Waheed Ullah Hafiz
PY - 2026
DA - 2026/10/29
JO - PPAR research
DO - 10.1155/ppar/9577380
UR - https://europepmc.org/article/MED/42960166
AB - Background The peroxisome proliferator-activated receptors (PPARs) and nuclear factor-κB (NF-κB) signaling axis serves as master molecular interface governing metabolic homeostasis and inflammatory resolution. Dysregulated reciprocal repression between PPAR-α/γ and NF-κB contributes to chronic inflammatory diseases, metabolic syndrome, and malignancy. Synthetic full agonists (e.g., thiazolidinediones and fibrates) are associated with clinical liabilities including adipogenesis, fluid retention, hepatotoxicity, and cardiovascular adverse effects, underscoring the need for safer modulators.Objective and rationale This structured narrative review provides a rigorous mechanistic synthesis of plant derived phytochemicals with selective PPAR modulator (SPPARM) like pharmacology. We elucidate how distinct chemical classes may achieve targeted NF-κB transrepression with reduced transcriptional liability, summarize available ligand receptor binding data, and critically evaluate translational hurdles.Methods A structured narrative review was conducted using a systematic style literature search across PubMed/MEDLINE, Scopus, and Web of Science from January 2000 through March 2026. In line with PRISMA 2020 principles for transparent reporting, original research articles were prioritized according to evidence type (clinical, preclinical, in vivo, and in vitro/in silico), with emphasis on pharmacodynamic metrics, binding kinetics (Ki, EC₅₀, and IC₅₀), receptor dependency validation (knockout, antagonism), and pharmacokinetic data.Results Chemically diverse phytochemicals including flavonoids, neolignans, stilbenoids and terpenoids exhibit partial or subtype selective PPAR agonism in reporter and binding assays. Mechanistically, many favor anti-inflammatory transrepression over full coactivator-dependent transactivation, with evidence for corepressor recruitment and inhibition of NF-κB nuclear translocation in selected models. However, integrated analysis reveals a persistent disconnect between submicromolar in vitro potency and negligible systemic exposure of free parent compound (low Cmax, extensive glucuronidation/sulfation), compounded by frequent reliance on unvalidated docking simulations and PPAR-independent NF-κB inhibition.Conclusion Phytochemicals with SPPARM-like pharmacology represent a promising but unvalidated paradigm for nonsteroidal inflammation control. Realizing their potential will require next-generation delivery systems (e.g., liposomes, nanoemulsions, and cyclodextrin complexes), mandatory genetic or pharmacological receptor validation, and biomarker-driven clinical trials that document target engagement at achievable human exposure levels.
SN - 1687-4757
SN - 1687-4765
ER -